208 related articles for article (PubMed ID: 32593959)
21. Severe CNS inflammation after discontinuation of natalizumab and start of daclizumab successfully treated with alemtuzumab.
Hümmert MW; Deppe J; Pul R; Wurster U; Schwenkenbecher P; Sühs KW; Bronzlik P; Stangel M; Skripuletz T
Mult Scler Relat Disord; 2018 May; 22():87-89. PubMed ID: 29631243
[TBL] [Abstract][Full Text] [Related]
22. The outlook for alemtuzumab in multiple sclerosis.
Williams T; Coles A; Azzopardi L
BioDrugs; 2013 Jun; 27(3):181-9. PubMed ID: 23558379
[TBL] [Abstract][Full Text] [Related]
23. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
24. Effect of thymopentin on peripheral blood T-lymphocytes subsets and on the clinical course of the disease in patients affected by multiple sclerosis.
Cognazzo A; Seliak D; Fruttero A
Riv Neurol; 1991; 61(3):110-5. PubMed ID: 1662825
[TBL] [Abstract][Full Text] [Related]
25. Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review.
Federle L; Puthenparampil M; Stenta G; Paolo G; Francesco P
Mult Scler Relat Disord; 2019 May; 30():262-264. PubMed ID: 30851640
[TBL] [Abstract][Full Text] [Related]
26. Hepatic microabscesses during CMV reactivation in a multiple sclerosis patient after alemtuzumab treatment.
Barone S; Scannapieco S; Torti C; Filippelli E; Pisani V; Granata A; Console D; Demonte G; Tallarico T; Polidoro S; Quattrone A; Valentino P
Mult Scler Relat Disord; 2018 Feb; 20():6-8. PubMed ID: 29272733
[TBL] [Abstract][Full Text] [Related]
27. Effector and regulatory B cells in Multiple Sclerosis.
Staun-Ram E; Miller A
Clin Immunol; 2017 Nov; 184():11-25. PubMed ID: 28461106
[TBL] [Abstract][Full Text] [Related]
28. Alemtuzumab in Covid era.
Iovino A; Olivieri N; Aruta F; Giaquinto E; Ruggiero L; Spina E; Tozza S; Manganelli F; Iodice R
Mult Scler Relat Disord; 2021 Jun; 51():102908. PubMed ID: 33812222
[TBL] [Abstract][Full Text] [Related]
29. Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden.
McKay KA; Piehl F; Englund S; He A; Langer-Gould A; Hillert J; Frisell T
JAMA Netw Open; 2021 Dec; 4(12):e2136697. PubMed ID: 34851401
[TBL] [Abstract][Full Text] [Related]
30. Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment.
Graf J; Ringelstein M; Lepka K; Schaller J; Quack H; Hartung HP; Aktas O; Albrecht P
Mult Scler; 2018 Nov; 24(13):1776-1778. PubMed ID: 30307371
[TBL] [Abstract][Full Text] [Related]
31. [Change of therapeutic algorithm in sclerosis multiplex based on two case reports].
Biernacki T; Bencsik K; Kincses ZT; Sandi D; Fricska-Nagy Z; Faragó P; Vécsei L
Ideggyogy Sz; 2017 Nov; 70(11-12):381-387. PubMed ID: 29870646
[TBL] [Abstract][Full Text] [Related]
32. Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy.
Crescenzo F; Marastoni D; Bovo C; Calabrese M
Mult Scler Relat Disord; 2020 Sep; 44():102372. PubMed ID: 32650121
[TBL] [Abstract][Full Text] [Related]
33. Autoimmune encephalitis following alemtuzumab treatment of multiple sclerosis.
Giarola B; Massey J; Barnett Y; Rodrigues M; Sutton I
Mult Scler Relat Disord; 2019 Feb; 28():31-33. PubMed ID: 30553166
[TBL] [Abstract][Full Text] [Related]
34. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab.
Saarela M; Senthil K; Jones J; Tienari PJ; Soilu-Hänninen M; Airas L; Coles A; Saarinen JT
Neurology; 2018 May; 90(18):849-851. PubMed ID: 29602914
[No Abstract] [Full Text] [Related]
35. [Effect of dihuang mixture on T-lymphocyte subsets in pheripheral blood and cerebrospinal fluid of patients with multiple sclerosis].
Gao M; Gao C; Yang N
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2002 Jun; 22(6):437-8. PubMed ID: 12585190
[No Abstract] [Full Text] [Related]
36. A cell-based assay for the detection of neutralizing antibodies against alemtuzumab.
Ali L; Saxena G; Jones M; Leisegang GR; Gammon L; Gnanapavan S; Giovannoni G; Schmierer K; Baker D; Kang AS
Biotechniques; 2020 Apr; 68(4):185-190. PubMed ID: 32096651
[No Abstract] [Full Text] [Related]
37. Trafficking of lymphocytes into the CNS.
Schwab N; Schneider-Hohendorf T; Wiendl H
Oncotarget; 2015 Jul; 6(20):17863-4. PubMed ID: 26255669
[No Abstract] [Full Text] [Related]
38. Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
Ranganathan U; Kaunzner U; Foster S; Vartanian T; Perumal JS
Mult Scler; 2018 Apr; 24(4):540-542. PubMed ID: 28287030
[TBL] [Abstract][Full Text] [Related]
39. Autoimmune diseases. The B cell slayer.
Matthews R
Science; 2007 Nov; 318(5854):1232-3. PubMed ID: 18033858
[No Abstract] [Full Text] [Related]
40. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.
Zhang X; Tao Y; Chopra M; Ahn M; Marcus KL; Choudhary N; Zhu H; Markovic-Plese S
J Immunol; 2013 Dec; 191(12):5867-74. PubMed ID: 24198283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
